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Abstract: The X-ray crystal structure of the adduct between the zinc metalloenzyme carbonic anhydrase
II (CA, EC 4.2.1.1) with the recently discovered natural product coumarin derivative 6-(1S-hydroxy-3-
methylbutyl)-7-methoxy-2H-chromen-2-one showed the coumarin hydrolysis product, a cis-2-hydroxy-
cinnamic acid derivative, and not the parent coumarin, bound within the enzyme active site. The bound
inhibitor exhibits an extended, two-arm conformation that effectively plugs the entrance to the enzyme
active site with no interactions with the catalytically crucial zinc ion. The inhibitor is sandwiched between
Phe131, with which it makes an edge-to-face stacking, and Asn67/Glu238sym, with which it makes several
polar and hydrogen bonding interactions. This unusual binding mode, with no interactions between the
inhibitor molecule and the active site metal ion is previously unobserved for this enzyme class and presents
a new opportunity for future drug design campaigns to target a mode of inhibition that differs substantially
from classical inhibitors such as the clinically used sulfonamides and sulfamates. Several structurally simple
coumarin scaffolds were also shown to inhibit all 13 catalytically active mammalian CA isoforms, with
inhibition constants ranging from nanomolar to millimolar. The inhibition is time dependent, with maximum
inhibition being observed after 6 h.
Introduction
In a recent communication1 one of our groups identified a
novel natural product inhibitor of the metalloenzyme carbonic
anhydrase (CA, EC 4.2.1.1)2 following screening of a large
number of natural product extracts using electrospray ionization
Fourier transform ion cyclotron resonance mass spectrometry
(ESI-FTICR-MS) as a bioaffinity screening tool. To the general
surprise, this CA inhibitor (CAI) isolated from the Australian
plant Leionema ellipticum Paul G. Wilson (Rutaceae) was a
coumarin derivative, namely 6-(1S-hydroxy-3-methylbutyl)-7-
methoxy-2H-chromen-2-one (1). Coumarins represent a novel
structural motif compared to all CAIs investigated to date.2
The CA family of enzymes is widespread all over the
phylogenetic tree with 16 different R-CA isozymes presently
known in mammals, among which 13 show catalytic activity.2
CAs catalyze a simple, yet critical, reaction: the reversible
hydration of carbon dioxide to a bicarbonate anion and a proton,
i.e., CO2 + H2O h HCO3- + H+. This reaction does not
proceed with an appreciable rate under physiological conditions
in the absence of CA. The Zn2+ core of CA serves an essential
function: it is a strong Lewis acid that binds to and activates
the hydrating water molecule. The Zn2+coordinated water has
a pKa of ∼7 compared to the pKa of bulk water of ∼14. CA
thus facilitates deprotonation of water to generate the strongly
basic hydroxide anion (OH-) which is the reactive species in
the hydration of CO2 leading to formation and release of
HCO3-.2 CAs are inhibited by sulfonamides, their bioisosteres
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(sulfamates, sulfamides, etc), metal complexing anions, phenols,
and thiophenols.2–4 These inhibitors bind as shown schematically
in Figure 1.
CAs are involved in numerous physiological and pathological
processes, including respiration and transport of CO2/bicarbonate
between metabolizing tissues and lungs, pH and CO2 homeo-
stasis, electrolyte secretion in a variety of tissues/organs,
biosynthetic reactions (such as gluconeogenesis, lipogenesis and
ureagenesis), bone resorption, calcification, tumorigenicity, and
many other physiological and pathological processes in humans,
as well as the growth and virulence of various fungal/bacterial
pathogens.3,4,9-11 In addition to the established role of CAIs as
diuretics and antiglaucoma drugs, it has recently emerged that
they have potential as anticonvulsant, antiobesity, anticancer,
and antiinfective drugs.2,4 Many of the CA isozymes involved
in these processes are important therapeutic targets with the
potential to be inhibited or activated to treat a wide range of
disorders.2,4,9–11 However a critical barrier to the design of CAIs
as therapeutic agents is related to the high number of isoforms,
their diffuse localization in many tissues/organs, and the lack
of isozyme selectivity of the presently available inhibitors.2–4
Thus the coumarin 1, a completely new structural motif for the
inhibition of this enzyme class,1 constitutes a valuable lead for
researchers working in the design of CAIs.
As coumarin 1 does not possess any of the zinc-anchoring
groups present in known CAIs, it appeared of great interest to
elucidate the CA inhibition mechanism of this new type of
derivative as well as to investigate the inhibition profile against
the mammalian catalytically active isoforms (13 such CAs are
known up until now).2 Herein we report a detailed inhibition
study with the simple coumarin 2, its 7-methoxy derivative 3
(the 7-methoxy groups is present in inhibitor 1 identified in the
Australian plant),1 and the originally reported CAI belonging
to this class, i.e., 6-(1S-hydroxy-3-methylbutyl)-7-methoxy-2H-
chromen-2-one 1.
Results and Discussion
CA Inhibition. Inhibition data for compounds 1-3 against
the 13 catalytically active mammalian (h ) human, m ) murine)
CA isoforms CA I-IV, VA, VB, VI, VII, IX, XII-XV are
presented in Table 1. The data have been obtained by a stopped-
flow technique monitoring the physiological reaction catalyzed
by these enzymes, i.e., CO2 hydration to bicarbonate and
protons.13 When assaying all other types of CAIs, such as
sulfonamides, inorganic complexing anions, phenols, or thiophe-
nols, an incubation time of 10-15 min is allowed for the
formation of the enzyme-inhibitor adduct.6,7,12,13 Working with
the same conditions, only a weak micromolar to millimolar
inhibition was observed with coumarins 1-3 (data not shown).
These observations prompted us to investigate the effect of the
incubation time between the enzymes and coumarins 1-3 on
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Figure 1. Schematic representation for the interactions of the four classes
of known CAIs with the enzyme active site: (A) Sulfonamides (and their
isosteres, sulfamates, sulfamides, etc.). (B) Inorganic anion inhibitors
(thiocyanate as an example). (C) Phenol(s).7 (D) Thiophenols (4-mercapto-
benzene-1,3-diol).8
Table 1. Inhibition of Mammalian Isozymes CA I-XV with
Coumarins 1-3 and trans-2-Hydroxy-cinnamic acid 5E by a
Stopped-Flow, CO2 Hydration Assay Method13
KI (µM)c
isozymea 1d 2d 3d 5Ee
hCA I 0.08 3.1 5.9 3.4
hCA II 0.06 9.2 0.07 9.3
hCA III >1000 >1000 161 nt
hCA IV 3.8 62.3 7. 8 nt
hCA VA 96.0 >1000 645 nt
hCA VB 17.7 578 48.6 nt
hCA VI 35.7 >1000 61.2 nt
hCA VII 27.9 >1000 9.1 nt
hCA IXb 54.5 >1000 767 nt
hCA XIIb 48.6 >1000 167.4 nt
mCA XIII 7.9 >1000 6.0 nt
hCA XIV 7.8 >1000 9.7 nt
mCA XV 93.1 >1000 >1000 nt
a h ) human; m ) murine isozyme; nt ) not tested. b Catalytic
domain. c Errors in the range of (5% of the reported data from three
different assays. d Preincubation of 6 h between enzyme and inhibitor.
e Preincubation 15 min between enzyme and inhibitor.
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CA inhibition. Inhibition constants were measured after 30 min,
1 h, 4 h, 6 h, and 24 h of incubation. For all investigated CA
isoforms we observed a progressive decrease of the inhibition
constants with the increase of the incubation time up to 6 h,
while from 6 to 24 h of incubation no further changes of KI
were evidenced. Table 1 reports the inhibition constants for
coumarins 1-3 following 6 h of incubation time with the
enzymes. Against isoforms I and II (ubiquitous, cytosolic CAs)2
1-3 show effective inhibition, with KI’s in the range 80 nM-5.9
µM (hCA I) and 60 nM-9.2 µM (hCA II), respectively. The
best hCA I and II inhibitor was always the natural product
coumarin 1. The remaining CA isoforms were typically inhibited
only weakly by the simple coumarin derivatives 2 and 3 (many
of them showed KI’s > 1000 µM) with few exceptions, notably
compound 3 against CA IV, VII, XIII, and XIV (KI’s in the
range 6.0-9.1 µM). The natural product 1 was an effective
inhibitor of all CAs investigated here (except CA III, KI > 1000
µM), with inhibition constants in the range 3.8-93.1 µM against
isoforms CA IV-XV (Table 1). The results observed with this
panel of coumarin derivatives show that there is a wide
distribution of inhibition constants for the same compound
against the various CA isoforms (e.g., 1 shows inhibition
constants in the range 59 nM-1000 µM). The inhibitory
properties of 1-3 are also dependent on the substitution pattern
of the coumarin ring, with the number of these groups
influencing inhibitory activity. The least active coumarin 2 lacks
substitution on the aromatic coumarin scaffold and coumarin 1
has two substituents (in the 6 and 7 positions), while coumarin
3 has a single substituent (7 position). Results presented in Table
1 demonstrate that substitution leads to an increase in the CA
inhibitory activity against many of the CA isozymes. Thus, this
newly identified chemotype in the context of CAIs is indeed
very promising for obtaining novel types of potent and
potentially more isozyme-selective inhibitors as compared to
the classical sulfonamide class of CA targetting drugs.
X-Ray Crystallography and Mass Spectrometry. To under-
stand the inhibitory mechanism with this new class of CAI, we
resolved the X-ray crystal structure (at a resolution of 2.0 Å)
of the most novel and potent of these inhibitorssthe natural
product coumarin 1sin adduct with the physiologically domi-
nant CA isoform,2 hCA II.17-22
Inspection of the electron density maps (Figure 2) at various
stages of the refinement showed features compatible with the
presence of one molecule of inhibitor bound within the active
site, but compound 1 could not be fitted in the observed electron
density. Instead, its hydrolysis product, the cis-2-hydroxy-4-
(1S-3-methylbutyl)-3-methoxy-cinnamic acid 4Z (Chart 1),
perfectly fits within this electron density (Figure 2).
Thus, the zinc bound hydroxide anion of the CA enzyme that
is responsible for the various catalytic activities of CAs2–4
including the esterase activity14 appears likely to have hydro-
lyzed the lactone ring of 1 leading to the formation of 4Z.
Interactions between the protein and Zn2+ ion were entirely
preserved in the hCA II-4Z adduct (data not shown).6,7 The
inhibitor 4Z was found bound at the entrance of the active site
cavity (Figure 3) with the two bulky arms of 4Z in an extended
conformation effectively plugging this entrance. The hydroxy-
pentyl arm orients toward the hydrophilic half of the active site,
while the cis-carboxyethylene arm orients toward the hydro-
phobic half.6,7 The methoxy and carboxyl moieties of the
inhibitor participate in several hydrogen bonds with the active
site (amino acid residues and water molecules). Moreover, the
1S-OH moiety of the hydroxypentyl arm makes a strong
dipole-dipole interaction with the carbonyl oxygen of the side
chain of Asn67. An edge-to-face (CH-π)15 stacking between
the aromatic ring of 4Z and the phenyl group of Phe131 was
also evidenced (with a distance of ∼3.5 Å between them). This
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Figure 2. Omit map corresponding to the hydrolyzed coumarin 1 (i.e., the
cis-2-hydroxy-cinnamic acid derivative 4Z), of some relevant CA II active
site residues and the Zn(II) ion (violet sphere).
Chart 1. Hydrolysis of Coumarins 1 and 2 to the Corresponding
Hydroxy-cinnamic Acid Derivatives 4Z and 5Z/5E
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latter amino acid residue is also important in the binding mode
of classical sulfonamide inhibitors to this enzyme.16 In summary,
hydrolyzed coumarin inhibitor 4Z is sandwiched between the
phenyl moiety of Phe131 and the side chains of Asn67 and
Glu238sym (the last amino acid residue from a symmetry related
enzyme molecule in the crystal packing) with three active site
water molecules further stabilizing the interaction of 4Z with
the enzyme, Figure 3. The hydrolysis product of coumarin 1,
the cis-2-hydroxy-cinnamic acid derivative 4Z, binds very
differently to the hCA II active site as compared the four classes
of known CAIs which interact with the metal ion or the water
coordinated to it (cf. Figure 1 and discussion above). This
different type of binding has not been evidenced before for any
CAI.
Several experiments afforded supplementary confirmation
regarding the proposed CA inhibition mechanism by coumarins,
as follows:
(i) Incubation of compounds 1-3 for 30 min-24 h with the
buffer used in the enzyme assay (in the absence of enzyme)
allowed us to observe the same weak inhibition measured with
the original compounds 1-3 when a 15 min incubation time
between enzyme and test inhibitor was employed (data not
shown). Thus, coumarins 1-3 are not hydrolyzed spontaneously
by the buffer used in the enzyme inhibition assay.
(ii) The hydrolysis product of coumarin 2, the simple trans-
2-hydroxy-cinnamic acid 5Z (as the sodium salt), has been
prepared by hydrolysis of 2 with sodium hydroxide, as described
in the literature.23 Compound 5Z was then investigated for its
inhibition of hCA I and II (Table 1). This hydrolyzed compound
inhibits the two CAs with the same magnitude as the parent
coumarin 2 (within the limits of experimental errors of the
assay). This observation is consistent with our proposal that the
true CA enzyme inhibitor is the hydrolyzed compound (e.g.,
4Z and 5Z and/or 5E), not the parent coumarins 1 and 2. It
should be mentioned that in solution the stable form of
hydrolyzed 2 is the E-isomer 5E,23 but literature data24 show
that the cis-trans isomerization of cinnamic acids is a readily
observed process, in various experimental conditions, mainly
in the presence of nucleophiles. It is noteworthy that, in the
X-ray crystal structure discussed above, we observe only the
Z-isomer of cinnamic acid 4Z to be stabilized when bound to
the enzyme active site, although in solution probably the
E-isomer would be favored.23,24 It should be also mentioned
that treatment of the sodium salt 5Z/5E with dilute acid leads
to the immediate formation of the original coumarin 2 (data
not shown) as described in the literature.23,24 Based upon these
data we propose the following to explain our experimental
observation that coumarins act as suicide inhibitors of CA.
Coumarins may undergo hydrolysis by the Zn2+-activated water
molecule/hydroxide ion of the enzyme cavity, which acts as a
very potent nucleophile.2 It is thus possible that the cis-2-
hydroxy-4-(1S-3-methylbutyl)-3-methoxy-cinnamic acid 4Z is
formed within the enzyme cavity by hydrolysis of bound 1,
which thereafter cannot bind effectively in the restricted space
near the Zn2+ ion due to its bulky pendant arms. A rearrange-
ment of the enzyme-inhibitor adduct may then occur (with the
movement of the bulky 4Z toward the exit of the active site),
leading to the effective binding of the hydrolyzed species of 1,
namely compound 4Z in the active site region in which we
observed it by X-ray crystallography. Thus, the initially weak
inhibitor 1 (a KI of 10.8 µM was measured for 1 when an
incubation time of 15 min between enzyme and inhibitor was
used; data not shown), by acting as a substrate to the enzyme
(23) Sethna, S. M.; Shah, N. M. Chem. ReV. 1945, 36, 1–62.
(24) Reed, G. A.; Dimmel, D. R.; Malcolm, E. W. J. Org. Chem. 1993,
58, 6364–71.
Figure 3. (A) The hCA II-4Z adduct. The protein is represented as green ribbon, the catalytic Zn(II) ion is represented as the violet sphere, and its three
protein ligands (His94, 96, and 119) are in CPK colors, as stick models. The inhibitor 4Z (in gold) and amino acid residues interacting with it (Phe131,
Asn67) are also evidenced, as well as His64, a residue involved in the catalytic cycle and acting as a proton shuttle 2–4 between the zinc-bound water
molecule and the buffer. (B) Detailed interactions between CA II and inhibitor 4Z when bound to the enzyme. The catalytic Zn(II) ion is shown as violet
sphere, with its three His ligands (His94, 96, and 119) and coordinated water molecule (red smaller sphere) also evidenced. The inhibitor molecule (gold)
interacts with three active site ordered water molecules (red spheres), with Phe131 and Asn67 (CPK colors) from the active site as well as with Glu238sym
(yellow) from a symmetry related enzyme molecule. The proton shuttle residue His64 is also shown (CPK colors).
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is transformed into an effective inhibitor 4Z (KI of 59 nM)
mediated by the esterase activity of CA II, leading us to propose
coumarins as suicide CA inhibitors.
(iii) ESI-MS analysis of bCA II (b ) bovine) in aqueous
ammonium acetate yielded the mass spectrum of Figure 4, entry
a. Peaks corresponding to the 11+ to 12+ charge states of bCA
II were observed as originally reported by Whitesides’ group,25
with the 11+ charge state predominating. This charge state
envelope (low charge states and few charge states) is typical
for bCA II when in a compact, tightly folded native structure.25,26
Next we incubated simple coumarin 2 with bCA II under
conditions of excess coumarin and obtained the mass spectrum,
Figure 4, entry b (15 min incubation) and entry c (23 h
incubation). If an inhibitor is combined with its target protein
then the noncovalent complex of [protein + inhibitor] may be
observed in the ESI mass spectrum. The mass difference
betweenthepeaksfor theunboundproteinandtheprotein-inhibitor
complex (∆m/z) can be multiplied by the charge state to give
directly the molecular weight of the binding inhibitor, i.e.,
MWinhibitor ) ∆m/z × z. A noncovalent complex of bCA II is
not observed with either parent coumarin 2 (MW ) 146) or
hydrolyzed coumarin (5Z or 5E) after 15 min, and the mass
spectrum looks similar to the free protein, Figure 4, entry b.
After 23 h we do however observe a strong noncovalent complex
of bCA II in the mass spectrum, Figure 4, entry c. The same
charge state envelope as that for bCA II (Figure 4, entry a) was
observed; however each charge state now consisted of a
grouping of peaks: a peak that corresponded to native bCA II
and, at a higher m/z value, a group of peaks that corresponded
to bCA II- complexes [bCA II-5Z/5E]. For example using the
11+ charge state, MWinhibitor is calculated as follows:
MWinhibitor )∆m ⁄ z × z) (2660.06- 2645.13) × 11) 164.2
Thus the observed MWinhibitor is 164; this corresponds to the
hydrolysis product of coumarin 2, i.e., 5Z and/or 5E as the
carboxylic acid.
(iv) Experiments were performed in which hCA II was
precomplexed with the low nanomolar sulfonamide inhibitor
acetazolamide (KI ) 12 nM)2 which was incubated for 1-3
days with coumarins 1 and 2. No hydrolysis products 4Z and
5Z/5E could be evidenced in these reaction mixtures by MS
(data not shown). This supports our premise that the catalytically
active enzyme is needed for the proposed lactone hydrolysis
which converts the less effective coumarins 1 and 2 to the potent
CA inhibitors 4Z and 5Z/5E. Inhibition is mediated by the active
site esterase chemistry of CA II.
Conclusion
6-(1S-Hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-
one (1) and structurally related, simple coumarins (2-3) act as
suicide inhibitors of 13 mammalian isoforms of the zinc
metalloenzyme CA, with inhibition constants from the nano-
molar to the millimolar range. The inhibition is time dependent,
(25) Gao, J.; Cheng, X.; Chen, R.; Sigal, G. B.; Bruce, J. E.; Schwartz,
B. L.; Hofstadler, S. A.; Anderson, G. A.; Smith, R. D.; Whitesides,
G. M. J. Med. Chem. 1996, 39, 1949–1955.
(26) Cheng, X.; Chen, R.; Bruce, J. E.; Schwartz, B. L.; Anderson, G. A.;
Hofstadler, S. A.; Gale, D. C.; Smith, R. D. J. Am. Chem. Soc. 1995,
117, 8859–8860.
Figure 4. (a) ESI mass spectrum of bCA II (30.9 µM) at charge state 12+ and 11+. (b) Mass spectrum of bCA II (30.9 µM)-coumarin 2 (1.2 mM) at charge
state 12+ and 11+ following incubation for 15 min. (c) Mass spectrum of bCA II (30.9 µM)-coumarin 2 (1.2 mM) at charge state 12+ and 11+ following
23 h of incubation.
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being observed after incubation of enzyme and coumarins for
4 h or longer. The X-ray crystal structure of the hCA II-6-
(1S-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one (4Z)
adduct showed the hydrolysis product of this coumarin bound
within the enzyme cavity in a region not observed earlier for
other classes of CA inhibitors, such as the sulfonamides,
complexing anions, phenols, and thiophenolssall of which bind
in a direct/indirect manner to the active site zinc cation. The
coumarin lacks classical zinc binding functional groups and
exhibits an unusual binding mode that may be exploited to
design isoform selective CA inhibitors. The inhibitor exhibits
an extended two-arm conformation that effectively plugs the
entrance to the active site. The inhibitor is sandwiched between
Phe131, with which it makes an edge-to-face stacking, and
Asn67/Glu238sym, with which it makes several polar interac-
tions and hydrogen bonds. Our results indicate that the develop-
ment of nonclassical CAIs based on the coumarin scaffold has
promise for obtaining isoform selective inhibitors and hence
exhibit lower side effects than currently marketed CAIs. As the
entrance of the active site cavity (where the hydrolyzed
coumarins bind) in the various CA isoforms is the region with
least conserved amino acid residues among the investigated
isozymes,3–6 this binding mode offers indeed the possibility to
design inhibitors with selectivity for some isoforms with
medicinal chemistry applications.
Experimental Protocols
Chemistry and CA Inhibition. Compound 1 was isolated from
the Australian plant as reported earlier,1 whereas other chemicals
(coumarins 2, 3; buffers; inorganic salts; bCA II; etc.) were the
highest purity available reagents from Sigma-Aldrich (Milan, Italy)
and used without further purification. All other enzymes (hCA
I-mCA XV) were recombinant ones produced in our laboratories
as described earlier.6–9,12,14
An Applied Photophysics stopped-flow instrument has been used
for assaying the CA-catalyzed CO2 hydration activity. Phenol red
(at a concentration of 0.2 mM) has been used as an indicator,
working at an absorbance maximum of 557 nm, with 20 mM Hepes
(pH 7.5) as buffer and 20 mM Na2SO4 (for maintaining constant
the ionic strength), following the initial rates of the CA-catalyzed
CO2 hydration reaction for a period of 10-100 s. The CO2
concentrations ranged from 1.7 to 17 mM for the determination of
the kinetic parameters and inhibition constants. For each inhibitor
at least six traces of the initial 5-10% of the reaction have been
used for determining the initial velocity. The uncatalyzed rates were
determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1 mM) were prepared
in distilled-deionized water, and dilutions up to 0.01 nM were
done thereafter with distilled-deionized water. Inhibitor and
enzyme solutions were preincubated together for 15 min-24 h at
room temperature (15 min) or 4 °C (all other incubation times)
prior to assay, to allow for the formation of the E-I complex or
for the eventual active site mediated hydrolysis of the inhibitor.
The inhibition constants were obtained by nonlinear least-squares
methods using PRISM 3, as reported earlier6,7,18 and represent the
mean from at least three different determinations.
Crystallization, X-ray Data Collection, and Refinement.
Crystals of the hCA II-4Z complex were obtained by using the
hanging-drop method for cocrystallizing the protein with the ligand,
as previously described.5b,6 A monochromatic experiment at the
CuR wavelength was performed on a crystal of CA II grown in
the presence of 1 (10 µM) by the rotation method on a PX-Ultra
sealed-tube diffractometer (Oxford Diffraction) at 100 K. The
crystal was diffracted up to a 2.0 Å resolution (resolution: 20.0-2.0
Å), with 15 970 (3194) unique reflections out of 75 057 (11 663)
reflections, and belonged to space group P21 (a ) 42.2 Å, b )
41.6 Å, c ) 72.2 Å, and R ) γ ) 90°,  ) 104.6°). The overall
completeness was 99.4 (98.0)%, Rsym)15.5 (31.9)%, multiplicity:
4.7 (3.7), F2/sig(F2))23.0 (3.4). The numbers in parentheses refer
to the values in the highest resolution shell (2.1-2.0 Å). Data were
processed with CrysAlis RED (Oxford Diffraction 2006).18,19 The
structure was analyzed by a difference Fourier technique, using
the PDB file 1CA2 as a starting model. The refinement was carried
out with the program REFMAC5;20 model building and map
inspections were performing using the COOT program.21 The final
model of the complex had an R-factor of 19.9% and R-free 26.8%
in the resolution range 20.0-2.0 Å, with an rms deviation from
standard geometry of 0.011 Å in bond lenghts and 1.36° in angles.
The correctness of stereochemistry was finally checked using
PROCHECK.22 Crystallographic parameters and refinement sta-
tistics are shown in Table 2.
Mass Spectrometry. Mass spectrometry was performed on an
APEX III 4.7 T FTICR mass spectrometer (Bruker Daltonics,
Billerica, MA, USA) fitted with an Apollo ESI source operated in
positive ion mode. XMASS NT V7.0.2 mass spectrometry software
on a PC platform was used for data acquisition. Broadband
excitation was used to analyze a mass range from m/z 100-4500,
with 256K, 128K, or 32K data points acquired. Samples were
infused into the ESI source at 2 µL min-1. Nitrogen was used as
both the drying gas (125 °C) and nebulizing gas. An Agilent ES
tuning mix (catalogue number G2421A) was used for an external
four-point calibration. Samples were prepared as follows: (i) bCA
II (30.9 µM) in 10 mM ammonium bicarbonate buffer (pH ) 8)
and (ii) bCA II (30.9 µM) in 10 mM ammonium bicarbonate buffer
(pH ) 8) + coumarin 2 (1.2 mM) (b ) bovine).
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Table 2. Crystallographic Parameters and Refinement Statistics
for the hCA II-4Z Adduct
parameter value
Crystal Parameter
space group P21
cell parameters a ) 42.2Å
b ) 41.6 Å
c ) 72.2 Å
 ) 104.6°
Data Collection Statistics (20.0-2.0 Å)
no. of total reflections 25 057
no. of unique reflections 15 970
completeness (%)a 99.4 (98.8)
F2/σ(F2) 23.0 (3.4)
R-sym (%) 15.5 (31.9)
Refinement Statistics (20.0-2.0 Å)
R-factor (%) 19.9
R-free (%)b 26.9
rmsd of bonds from ideality (Å) 0.011
rmsd of angles from ideality (deg) 1.36
a Values in parentheses relate to the highest resolution shell (2.1-2.0
Å). b Calculated using 5% of data.
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